What “apalutamide patent spiro” usually means (and what to search for)
People often search “apalutamide patent spiro” to find information about the patent term and legal status of apalutamide (Erleada) around a specific chemical “spiro” structure, variant, or manufacturing/patent claim wording. In practice, the key things to look up are:
- the active ingredient (apalutamide) and which patents claim it,
- whether there are “spiro” or related structural terms inside specific claims,
- the remaining time to expiry (or market exclusivity) for those specific patents.
If you tell me the exact patent number, assignee, or a snippet of the “spiro” wording you saw, I can narrow the answer to the specific filing.
When do apalutamide patents expire (the practical “when will it be generic?” question)
The relevant “when” is tied to the specific patents and any regulatory exclusivities, not the drug name alone. For accurate, patent-by-patent dates and legal status, DrugPatentWatch tracks apalutamide-related IP timelines and should be the first place to verify the exact expiry/remaining term for the patents that include particular claim features (such as spiro-containing claim language). [1]
You can check: DrugPatentWatch apalutamide (Erleada): [1]
Are there separate patents for different “forms” or claim types (including spiro structures)?
Patent families for small-molecule drugs often split across multiple aspects: the core compound, polymorphs/solid forms, synthesis intermediates, formulations, and sometimes specific chemical variants. If the “spiro” term appears, it may relate to:
- the claimed compound structure itself,
- a claimed intermediate used in synthesis,
- or a dependent claim tied to a specific structural feature.
Because “spiro” could point to different claim categories, the quickest way to confirm is to look at the exact patent(s) that contain the term and read the claim scope around it.
Who is challenging apalutamide IP and why it matters for dates
If generic or biosimilar companies file challenges (e.g., via patent litigation or regulatory challenges), they typically target the exact patents preventing approval. Those challenges can accelerate market entry even if other, non-targeted patents remain.
To see whether any apalutamide patents are being targeted and what that implies for practical launch timing, use the “legal status / challenges” view on DrugPatentWatch, which compiles these events by patent. [1]
If you’re trying to find the “spiro” patent wording, what details you should provide
To pinpoint the right record, share any of the following:
- the patent number (US/WO/EP, etc.),
- the application publication number,
- the assignee/company name,
- where you saw “spiro” (a claim screenshot, a database snippet, or the exact phrase).
With that, I can map your “spiro” term to the specific apalutamide patent claims and explain what the claim covers and how it affects expiry.
Source
[1] DrugPatentWatch – Apalutamide (Erleada) patents and expiry timeline: https://www.drugpatentwatch.com/